timothy sykes logo

Stock News

ImmunityBio’s Stock Tumult: Buy or Hold?

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Ellis Hobbs Fact-checked by Matt Monaco
ImmunityBio’s Stock Tumult: Buy or Hold? Thumbnail

ImmunityBio Inc.’s stocks have been trading down by -3.81 percent amid increased market pessimism.

Key Market Events Impacting IBRX

  • The Food and Drug Administration (FDA) sent a Refusal to File (RTF) letter to ImmunityBio for ANKTIVA plus BCG application, stirring up market uncertainties among shareholders with its unexpected grip on papillary disease treatment plans.

  • The company’s swift response, seeking an urgent meeting with the FDA, reflects their intent to address inconsistencies and bring clarity to previous guidance, indicating potential resolution.

  • A dramatic fall of around 8% in the stock price followed the announcement, shaking investor confidence yet urging strategic thinkers to ponder a possible potential reversal.

Candlestick Chart

Live Update At 17:04:02 EST: On Tuesday, May 06, 2025 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending down by -3.81%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Snapshot of ImmunityBio’s Financial Landscape

As a trader, it’s crucial to understand that the path to success isn’t always straightforward. There are going to be challenges and setbacks along the way. As millionaire penny stock trader and teacher Tim Sykes says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” By learning from every misstep and celebrating every victory, traders can refine their approach and enhance their skills over time. The key to long-term profitability lies in adaptability and continuous learning, drawing valuable insights from each experience in the market.

ImmunityBio recently found itself in hot water after receiving that RTF letter, casting a shadow over its pursuit to cement ANKTIVA as a viable treatment. The market, quick to react, dwindled the stock price, eroding investor gains in the blink of an eye. The financials, however, tell a broader story.

Earnings Performance and Financial Metrics

Revenue and Growth Insights: The company saw revenue streams at $14.75M, pointing to challenges in revenue generation vis-a-vis their expanding endeavors. A contrasting indicator shows 150% and 221% revenue growth over three and five years respectively. This growth facade, however, pales against intensifying competition and partnering dilemma uncertainties that might hinder future earnings.

Valuation and Profit Prospects: On evaluation, measures like enterprise value standing robust at $5.27B seem hopeful but are capped by distressing profit margins. Negative price-to-sales ratios and absent price-to-cash flow values paint a perplexing scenario that baffles even seasoned investors. These metrics, coupled with a challenging cash flow sheet, taunt profitability.

Liquidity and Capital Structure: The company’s current ratio of 3.4, combined with a quick ratio of 2.8, sketch an optimistic liquidity profile, implying sufficient assets to cover short-term obligations. Yet, that doesn’t ring true with the abysmally negative $116.10M worth of pretax profit margins, implying a stormy ride.

Can the boost in current assets guard against their whopping liabilities? While investors root for quick wins, ImmunityBio battles its own demons—managing long-standing financial woes while pushing innovative cancer treatments to market forefronts.

Unraveling News and Market Impact

FDA Letter Sparks Panic:

On May 5, 2025, panic ensued with the news of ImmunityBio receiving an RTF for its sought-after sBLA for ANKTIVA plus BCG. This shockwave echoed across investor circles as confidence took a steep dip. Aggressive selling dropped the stock price by 8% the day after.

This rejection not only squashed immediate hopes for bolstered revenue channels but also signaled potentially stringent outlooks from regulatory bodies. Investors observed this new hurdle as a paramount setback, sparking worries about future R&D investments and project viability.

Yet, some experts beg to differ. They interpret ImmunityBio’s quick decision to seek an FDA meeting as a testament to the company’s resilience and strategic foresight. An affirmative outcome from this meeting could lead to the reclamation of lost investor confidence. For vigilant speculators, this could be viewed as both a cautionary tale and a window of preventive opportunity, contingent on ImmunityBio’s navigational strategies.

More Breaking News

Financial Reports: Deception in Opulence or a Strategic Play?

Even amidst financial conundrums, ImmunityBio’s ambitions are unchecked. Capital expenditure rises reveal an ongoing pursuit of innovation, with $2.11M allocated to strategic prospects. The firm recently saw a net income hit, answering many investors’ worries with a staggering $59.17M loss—an insight into its battle of balancing research commitments against profitability odds.

Operational cash flows tell their own tale. Despite earning revenue, ImmunityBio is porous with cash burn. Investors, entangled in this vortex of ambitions and financial mishaps, seem tasked with separating ostentative projections from grounded reality. What puzzles the market is how this cash flux, paired with heavy R&D investments, stacks against market inflections.

Can ImmunityBio’s growth potential, laced with promising therapies, outweigh its financially-strapped inhibitors? The narrative seems on edge, with dubious eyes glued to FDA’s concluding decisions and ImmunityBio’s strategic crystal ball.

What’s Next for ImmunityBio?

With turbulent waters ahead, market traders eye ImmunityBio cautiously, weighing it against a sea of seasoned pharmaceutical gladiators. The FDA’s recent stance amplifies trader skepticism, yet promises newfound avenues whereby regulatory meetings beckon resolutions. As caution continues to shadow optimism, this biotech tempest leaves onlookers pondering ImmunityBio’s fate amid looming prospects and daunting tribulations ahead.

As millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.” This sentiment resonates deeply in the current landscape. Final decisions, pivots, and regulatory leaps might very well determine ImmunityBio’s trajectory. Traders must bear meticulous vigilance, perhaps seizing quantifiable prospects minute by minute, steering their predictions with ImmunityBio’s ambitious sails, ever mindful of protecting their capital in the face of uncertainty.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”